BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported

12/30 .2021

BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported

BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported
BioKangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Was Approved As Booster Dose in Indonesia

01/11 .2022

BioKangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Was Approved As Booster Dose in Indonesia

BioKangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Was Approved As Booster Dose in Indonesia
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.

09/12 .2024

Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.

Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market
BioKangtai’s Shenzhen Guangming Base has passed the GMP certification in the Philippines

07/06 .2022

BioKangtai’s Shenzhen Guangming Base has passed the GMP certification in the Philippines

National Liver Love Day: Timely vaccination of hepatitisB vaccine…National Liver Love Day: Timely vaccination of hepatitisB vaccine…
BioKangtai passed the EU QP audit quality management system and reached the EU GMP standard

05/08 .2022

BioKangtai passed the EU QP audit quality management system and reached the EU GMP standard

BioKangtai passed the EU QP audit quality management system and reached the EU GMP standard
BioKangtai's Inactivated COVID-19 Vaccine (Vero Cell) is Approved Homologous Booster Vaccination in China

02/21 .2022

BioKangtai's Inactivated COVID-19 Vaccine (Vero Cell) is Approved Homologous Booster Vaccination in China

BioKangtai's Inactivated COVID-19 Vaccine (Vero Cell) is Approved Homologous Booster Vaccination in China
< 1234 >